Pharmaceutical Technology18h
Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership
Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.
Pharmaceutical Technology22h
Tevimbra by BeiGene for Gallbladder Cancer: Likelihood of Approval
Tevimbra is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...
Pharmaceutical Technology22h
Androgenetic Alopecia by Cosmo Pharmaceuticals for Androgenic Alopecia: Likelihood of Approval
Cosmo Pharmaceuticals (Cosmo) develops drugs for the treatment of gastrointestinal diseases and dermatology. It develops pharmaceutical products based on its multi-matrix technology. The company’s ...
Pharmaceutical Technology22h
ABBV-47D11 by AbbVie for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
ABBV-47D11 is under clinical development by AbbVie and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have ...
Pharmaceutical Technology22h
Tumorad by Spago Nanomedical for Metastatic Breast Cancer: Likelihood of Approval
Tumorad is under clinical development by Spago Nanomedical and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 32% phase ...
Pharmaceutical Technology22h
MK-6194 by Merck for Vitiligo: Likelihood of Approval
MK-6194 is under clinical development by Merck and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo have a 42% phase transition success rate (PTSR) indication ...